Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy.
His AbbVie purchase was a big move into a high-yielding dividend stock.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.